DSIP

Name: DSIP
Availability: InStock

2mg vial

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. Across decades of research it has been studied for slow-wave sleep promotion, circadian regulation, stress-axis modulation and analgesic effects, with a notably benign tolerability profile.

Select size

Checking availability…

Researched for

Increased slow-wave (delta) sleep duration in EEG studies
Reduced sleep latency and improved sleep continuity
Attenuation of stress-induced cortisol elevation
Reported analgesic activity in chronic-pain research
Possible normalisation of disrupted circadian rhythms
Favourable tolerability with minimal next-day sedation

Mechanism of action

Exact receptor target remains uncharacterised. Demonstrated effects include modulation of the HPA axis (reduced ACTH/cortisol output), normalisation of delta-wave EEG architecture, and interaction with opioidergic and GABAergic systems.

Research protocol

Common research protocols use 100–300mcg subcutaneously 30–60 minutes before bed, or intranasally. Cycles typically run 4–8 weeks with intermittent use rather than daily long-term administration.

Half-life

Plasma half-life is short (approx. 7–20 minutes), but downstream effects on sleep architecture persist well beyond clearance.

Reconstitution

Reconstitute a 5mg vial with 2–5mL bacteriostatic water for a 1–2.5mg/mL working concentration. Swirl gently.

Storage

Lyophilised: 2–8°C, stable 18–24 months; -20°C for long-term storage. Reconstituted: 2–8°C, protect from light, use within 30 days.

Research considerations

• Human RCT data is limited and dated; most evidence is mid-20th-century research.
• Receptor pharmacology remains poorly characterised - long-term safety profile is not well established.
• Mild dizziness or transient headache reported anecdotally at higher doses.